Tác động của phẫu thuật đường tiêu hóa đến độ nhạy insulin và sự tiết insulin

Sims EA, Danforth Jr E, Horton ES, et al. Endocrine and metabolic effects of experimental obesity in man. Recent Prog Horm Res. 1973;29:457–96. National Heart, Lung and Blood Institute. Morbidity & mortality: 1998 chartbook on cardiovascular, lung, and blood diseases. Rockville, Maryland: US Department of Health and Human Services, National Institutes of Health, 1998. Wild S, Roglic G, Green A, Sicree R, King H. Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care. 2004;27:1047–53. Anjum Q. Diabesity- a future pandemic. J Pak Med Assoc. 2011;61:321. NIH conference. Gastrointestinal surgery for severe obesity. Consensus Development Conference Panel. Ann Intern Med. 1991,115:956–961. Buchwald H, Estok R, Fahrbach K, et al. Weight and type 2 diabetes after bariatric surgery: systematic review and meta-analysis. Am J Med. 2009;122:248–56. Dorman RB, Serrot FJ, Miller CJ, et al. Case-matched outcomes in bariatric surgery for treatment of type 2 diabetes in the morbidly obese patient. Ann Surg. 2012;255:287–93. Dixon JB, O’Brien PE, Playfair J, et al. Adjustable gastric banding and conventional therapy for type 2 diabetes: a randomized controlled trial. JAMA. 2008;299:316–23. Sesti G, Folli F, Perego L, et al. Effects of weight loss in metabolically healthy obese subjects after laparoscopic adjustable gastric banding and hypocaloric diet. PLoS One. 2011;6:e17737. • Rao RS, Yanagisawa R, Kini S. Insulin resistance and bariatric surgery. Obes Rev 2012;13:316–328. This is a very accurate and thorough systematic review of available data in the literature on behavior of insulin resistance after the different bariatric operations. In addition the Authors discuss critically the various methods of measurement and the mechanisms of improvement of insulin resistance and its relation to the changes of incretins and gastrointestinal hormones. Scott WR, Batterham RL. Roux-en-Y gastric bypass and laparoscopic sleeve gastrectomy: understanding weight loss and improvements in type 2 diabetes after bariatric surgery. Am J Physiol Regul Integr Comp Physiol. 2011;301:R15–27. Hutter MM, Schirmer BD, Jones DB, et al. First report from the American College of Surgeons Bariatric Surgery Center Network: laparoscopic sleeve gastrectomy has morbidity and effectiveness positioned between the band and the bypass. Ann Surg. 2011;254:410–20. •• Schauer PR, Kashyap SR, Wolski K, et al. Bariatric surgery versus intensive medical therapy in obese patients with diabetes. N Engl J Med 2012;366:1567–1576. This is one of the two much-needed, randomized control trials in T2DM patients, which have been published recently, comparing SG and RYGB to intensive medical therapy. At one year follow-up, the surgical groups fared by far much better than medical groups providing level 1 evidence to the role of the surgical option to the treatment of the type 2 obese diabetic patients. Abbatini F, Rizzello M, Casella G, et al. Long-term effects of laparoscopic sleeve gastrectomy, gastric bypass, and adjustable gastric banding on type 2 diabetes. Surg Endosc. 2010;24:1005–10. Stefater MA, Sandoval DA, Chambers AP, et al. Sleeve gastrectomy in rats improves postprandial lipid clearance by reducing intestinal triglyceride secretion. Gastroenterology. 2011;141:939–49. •• Chambers AP, Jessen L, Ryan KK, et al. Weight-independent changes in blood glucose homeostasis after gastric bypass or vertical sleeve gastrectomy in rats. Gastroenterology. 2011;141:950–958. This experimental study in obese rats after either RYGB or SG was very elegantly designed and was able to demonstrate that the restored glucose homeostasis was in part weight-independent and linked to enhanced GLP-1 and insulin secretion. Larder R, O’Rahilly S. Shedding pounds after going under the knife: guts over glory-why diets fail. Nat Med. 2012;18:666–7. •• Mingrone G, Panunzi S, De Gaetano A, et al. Bariatric surgery versus conventional medical therapy for type 2 diabetes. N Engl J Med 2012;366:1577–1585. This is one of the two much-needed, prospective randomized trials in T2DM subjects comparing RYGB and BPD to conventional medical therapy. It is to be mentioned that the inclusion criteria were selected following the guidelines indicated by the NIH Consensus Conference of 1991 which, although widely endorsed, were never validated. At two years follow-up the surgical patients outperformed in a very remarkable way the medical group and evidence was provided that neither weight change nor duration of diabetes were not significant predictors of diabetes reversal. Campos GM, Rabl C, Peeva S, et al. Improvement in peripheral glucose uptake after gastric bypass surgery is observed only after substantial weight loss has occurred and correlates with the magnitude of weight lost. J Gastrointest Surg. 2010;14:15–23. Camastra S, Gastaldelli A, Mari A, et al. Early and longer term effects of gastric bypass surgery on tissue-specific insulin sensitivity and beta cell function in morbidly obese patients with and without type 2 diabetes. Diabetologia. 2011;54:2093–102. Nannipieri M, Mari A, Anselmino M, et al. The role of beta-cell function and insulin sensitivity in the remission of type 2 diabetes after gastric bypass surgery. J Clin Endocrinol Metab. 2011;96:E1372–9. Jorgensen NB, Jacobsen SH, Dirksen C, et al. Acute and long-term effects of Roux-en-Y gastric bypass on glucose metabolism in subjects with type 2 diabetes and normal glucose tolerance. Am J Physiol Endocrinol Metab 2012 [Epub ahead of print] Kim MK, Lee HC, Lee SH, et al. The difference of glucostatic parameters according to the remission of diabetes after Roux-en-Y gastric bypass. Diabetes Metab Res Rev 2012 [Epub ahead of print]. Lin E, Liang Z, Frediani J, et al. Improvement in ß-cell function in patients with normal and hyperglycemia following Roux-en-Y gastric bypass surgery. Am J Physiol Endocrinol Metab. 2010;299:E706–12. Service GJ, Thompson GB, Service FJ, et al. Hyperinsulinemic hypoglycemia with nesidioblastosis after gastric-bypass surgery. N Engl J Med. 2005;353:249–54. Kellogg TA, Bantle JP, Leslie DB, et al. Postgastric bypass hyperinsulinemic hypoglycemia syndrome: characterization and response to a modified diet. Surg Obes Relat Dis. 2008;4:492–9. Salinari S, Bertuzzi A, Guidone C, et al. Insulin sensitivity and secretion changes after gastric bypass in normotolerant and diabetic obese subjects. Ann Surg 2012, in press. Kindel TL, Yoder SM, Seeley RJ, et al. Duodenal-jejunal exclusion improves glucose tolerance in the diabetic, Goto-Kakizaki rat by a GLP-1 receptor-mediated mechanism. J Gastrointest Surg. 2009;13:1762–72. Speck M, Cho YM, Asadi A, Rubino F, Kieffer TJ. Duodenal-jejunal bypass protects GK rats from {beta}-cell loss and aggravation of hyperglycemia and increases enteroendocrine cells coexpressing GIP and GLP-1. Am J Physiol Endocrinol Metab. 2011;300:E923–32. Laferrère B, Teixeira J, McGinty J, et al. Effect of weight loss by gastric bypass surgery versus hypocaloric diet on glucose and incretin levels in patients with type 2 diabetes. J Clin Endocrinol Metab. 2008;93:2479–85. Laferrère B. Do we really know why diabetes remits after gastric bypass surgery? Endocrine. 2011;40:162–7. Scopinaro N, Marinari GM, Camerini GB, et al. Specific effects of biliopancreatic diversion on the major components of metabolic syndrome: a long-term follow-up study. Diabetes Care. 2005;28:2406–11. Guidone C, Manco M, Valera-Mora E, et al. Mechanisms of recovery from type 2 diabetes after malabsorptive bariatric surgery. Diabetes. 2006;55:2025–31. Salinari S, Bertuzzi A, Asnaghi S, et al. First-phase insulin secretion restoration and differential response to glucose load depending on the route of administration in type 2 diabetic subjects after bariatric surgery. Diabetes Care. 2009;32:375–80. Salinari S, Bertuzzi A, Iaconelli A, et al. Twenty-four hour insulin secretion and beta cell NEFA oxidation in type 2 diabetic, morbidly obese patients before and after bariatric surgery. Diabetologia. 2008;51:1276–84. Mingrone G, Nolfe G, Gissey GC, et al. Circadian rhythms of GIP and GLP1 in glucose-tolerant and in type 2 diabetic patients after biliopancreatic diversion. Diabetologia. 2009;52:873–81. Adams TD, Gress RE, Smith SC, et al. Long-term mortality after gastric bypass surgery. N Engl J Med. 2007;357:753–61. Lim EL, Hollingsworth KG, Aribisala BS, et al. Reversal of type 2 diabetes: normalisation of beta cell function in association with decreased pancreas and liver triacylglycerol. Diabetologia. 2011;54:2506–14. Kelley DE, Wing R, Buonocore C, et al. Relative effects of calorie restriction and weight loss in noninsulin-dependent diabetes mellitus. J Clin Endocrinol Metab. 1993;77:1287–93. Pournaras DJ, Osborne A, Hawkins SC, et al. Remission of type 2 diabetes after gastric bypass and banding: mechanisms and 2 year outcomes. Ann Surg. 2010;252:966–71. Yki-Järvinen H. Type 2 diabetes: remission in just a week. Diabetologia. 2011;54:2477–9. Rubino F, Schauer PR, Kaplan LM. Metabolic surgery to treat type 2 diabetes: clinical outcome and mechanisms of action. Annu Rev Med. 2010;61:393–411.